Strong Top-Line Revenue Growth
Revenue grew 16.7% year-over-year to $1.65B in Q1 FY2026 from $1.41B in the prior year period, reflecting robust demand across Edwards' product portfolio, particularly in structural heart therapies.
Edwards Lifesciences Corp is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: Edwards Lifesciences delivered strong Q1 FY2026 revenue growth of 16.7% to $1.65B, with operating income surging 21.0%, though operating cash flow dropped sharply by 84.4% to $43.8M amid aggressive share buybacks of $421.8M.
Drawn from management commentary in the Q1 2026 10-Q:
Revenue grew 16.7% year-over-year to $1.65B in Q1 FY2026 from $1.41B in the prior year period, reflecting robust demand across Edwards' product portfolio, particularly in structural heart therapies.
Operating income rose 21.0% YoY to $477.6M, outpacing revenue growth, with operating margin expanding approximately 100 basis points to 29.0% from 27.9%, indicating improving operational efficiency despite rising SG&A costs.
SG&A expenses increased 12.1% YoY to $522.2M, representing a meaningful cost headwind, though the company managed to expand operating margins by controlling R&D growth to just 3.4% YoY at $263.3M.
Revenue
$1.65B
++16.70% YoY
EPS (Basic)
$0.66
++8.20% YoY
Gross Margin
78.0%
-0.65% YoY
Operating Income
$477.6M
++20.97% YoY
Add EW to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.